Holen Sie sich die Stockscreener-App
30.98
0.10%
0.03
Handel nachbörslich:
30.89
-0.09
-0.29%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$30.95
Offen:
$31.01
24-Stunden-Volumen:
3.77M
Relative Volume:
0.93
Marktkapitalisierung:
$15.82B
Einnahmen:
$17.28B
Nettoeinkommen (Verlust:
$108.00M
KGV:
154.90
EPS:
0.2
Netto-Cashflow:
$391.00M
1W Leistung:
+5.30%
1M Leistung:
+4.52%
6M Leistung:
-13.17%
1J Leistung:
-19.93%
1-Tages-Spanne:
$30.51
$31.02
1-Wochen-Bereich:
$29.24
$31.20
52-Wochen-Spanne:
$28.34
$44.01
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(847) 948-2000
Adresse
ONE BAXTER PKWY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
30.98 | 15.82B | 17.28B | 108.00M | 391.00M | 0.20 |
|
ISRG
Intuitive Surgical Inc
|
592.64 | 211.09B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
237.38 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.37 | 41.73B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
239.78 | 35.23B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
336.34 | 24.40B | 2.88B | 499.60M | 321.60M | 6.74 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
China Infusion Systems (Pumps & Pump Disposables) Market Outlook to 2033: Key Companies in China, Pipeline Products, Financial Deals Landscape, Recent Developments & More - GlobeNewswire Inc.
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL
Baxter restarts dialysis solutions production at North Cove plant - MSN
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Should You Hold Baxter International (BAX) for the Long Term? - MSN
Baxter International Inc. (NYSE:BAX) Receives $40.45 Consensus Price Target from Analysts - MarketBeat
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Small divestitures, acquisitions ahead as Baxter refines strategy - Crain's Chicago Business
Infusion Therapy Market Growth Trends: Regional Breakdown - openPR
Baxter International Inc. (NYSE:BAX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Baxter International (XSWX:BAX) 3-Year EPS without NRI Grow - GuruFocus.com
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Unparalleled Research on Immunoglobulin Market by 2024-2031 | Baxter international Inc., CSL Ltd. - EIN News
U.S. Elastomeric Infusion Pumps Market Set to Witness Significant Growth by 2025-2032: Baxter International - EIN News
U.S. Intravenous Solutions Market Is Booming Worldwide - openPR
Baxter International Inc. stock rises Wednesday, still underperforms market - MarketWatch
How Italian Furniture Maker Baxter Balances Tradition and Innovation - Prestige Online Thailand
Baxter International Inc. stock rises Monday, still underperforms market - MarketWatch
Immunoglobulin Market Generated Opportunities, Future Scope by 2024-2031| Baxter international Inc., CSL Ltd. - EIN News
Baxter International Inc. (NYSE:BAX) Shares Sold by Everence Capital Management Inc. - MarketBeat
Plasma Expander Market Overall Study Report 2025-2032 | Baxter - openPR
Baxter International Inc. stock rises Friday, still underperforms market - MarketWatch
Centre Asset Management LLC Sells 21,904 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Inc. (NYSE:BAX) Short Interest Up 6.1% in December - MarketBeat
Earnings Review and Free Research Report: Baxter’s Revenue Grew 6%; EPS Rocketed 96% - AccessWire
BAXTER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Baxter International In - AccessWire
How Is Baxter International's Stock Performance Compared to Other Medical Devices Stocks? - MSN
Investors in Baxter International (NYSE:BAX) have unfortunately lost 64% over the last three years - Simply Wall St
Early Alert: Solution Set Issue from Baxter Healthcare Corporation - FDA.gov
Baxter International (NYSE:BAX) Sets New 52-Week LowWhat's Next? - MarketBeat
Baxter stock touches 52-week low at $28.6 amid market challenges - Investing.com Australia
Should We Be Cautious About Baxter International Inc.'s (NYSE:BAX) ROE Of 1.6%? - Yahoo Finance
Prolotherapy Market Overall Study Report 2024-2031 | Pfizer - openPR
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):